Use of Baysient iDose Found to Improve Infliximab Durability and Reduce Immunogenicity
For patients living with inflammatory bowel disease (IBD), Infliximab (IFX), a monoclonal antibody, has emerged as an efficient treatment for disease activity reduction and IBD patient life quality improvement. However, while IFX is an effective treatment for some patients, a…

